Clinical trial
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk…
NCT00400517 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00400517 |
|---|---|
| Title | GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer |
| Official title | Phase II Trial of Neoadjuvant GM-CSF + Thalidomide in High-Risk Patients With Prostate Cancer Undergoing Prostatectomy |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | sargramostim, thalidomide, conventional surgery, neoadjuvant therapy |
| Enrollment | 28 |
| Start date | Mar 1, 2003 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 17, 2006 |
| Last update posted | Aug 28, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: